This interaction may give rise to a ‘second wave’ of tumour reactive T cells, including CD8+ CTLs, that are directed against unknown tumour/tissue-specific antigens (cross presentation) (Markiewicz et al, 2001). The gene discussed is CD8A; the disease is neoplasm.